$CYTOF

Auris Medical Holding AG

CIK:0001601936|SEC Filings

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) - USD ($)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

^[1]

Dec. 31, 2022

Profit or loss [abstract]

Other operating income

$ 75,292

$ 284,462

$ 9,766

^[1]

Research and development

(3,727,005)

(3,378,312)

(15,310,545)

^[1]

General and administrative

(3,199,201)

(3,490,568)

(3,561,964)

^[1]

Operating loss

(6,850,914)

(6,584,418)

(18,862,743)

^[1]

Finance income

3,327

394,092

592,041

^[1]

Finance expense

(836,788)

(1,856,956)

(1,268,108)

^[1]

Share of loss of an associate

(773,373)

(44,025)

^[2]

^[1],[2]

Loss before tax

(8,457,748)

(8,091,307)

(19,538,810)

^[1]

Income tax gain

8,292

^[1]

Net loss from continuing operations

(8,457,748)

(8,091,307)

(19,530,518)

^[1]

Profit/(loss) after tax from discontinued operations

^[1]

3,785,047

(8,247,925)

Net loss attributable to owners of the Company

(8,457,748)

(4,306,260)

^[2]

(27,778,443)

^[1],[2]

Remeasurements of defined benefit liability, net of taxes of $0

(250,448)

34,683

462,070

^[1]

Items that are or may be reclassified to profit or loss

Foreign currency translation differences, net of taxes of $0

445,295

360,862

(869,924)

^[1]

Share of other comprehensive income of an associate

19,295

7,645

^[1]

Other comprehensive income/(loss), net of taxes of $0

214,142

403,190

(407,854)

^[1]

Total comprehensive loss attributable to owners of the Company

$ (8,243,606)

$ (3,903,070)

$ (28,186,297)

^[1]

Loss per share

Basic loss per share (in Dollars per share)

$ (2.99)

$ (8.77)

$ (610.03)

^[1]

Diluted loss per share (in Dollars per share)

(2.99)

(8.77)

(610.03)

^[1]

Basic loss per share from continuing operations (in Dollars per share)

(2.99)

(16.47)

(428.9)

^[1]

Diluted loss per share from continuing operations (in Dollars per share)

$ (2.99)

$ (16.47)

$ (428.9)

^[1]

[1]	Amounts have been re-presented from those previously published to reflect the change in the Company’s presentation currency from Swiss francs to US dollars (see Note 2).
[2]	Amounts have been represented from those previously published to reflect the change in the Company’s presentation currency from Swiss francs to US dollars (see Note 2).

Consolidated Statement of Cash Flows - USD ($)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Cash flows from operating activities

Net loss

$ (8,457,748)

$ (4,306,260)

^[1],[2]

$ (27,778,443)

^[1],[2]

Adjustments for:

Depreciation

127,054

132,781

^[1]

124,489

^[1]

Impairment of intangible assets

^[1]

12,981,307

^[1]

Share in result of an associate

773,373

44,025

^[1],[2]

Loss / (gain) on disposal of discontinued operations

(5,793,584)

^[1]

Deferred income

^[1]

976,126

^[1]

Unrealized foreign currency exchange loss/(gain), net

573,392

200,722

^[1]

(48,258)

^[1]

Net interest expense

8,366

1,121,524

^[1]

933,666

^[1]

Share based payments

532,081

422,274

^[1]

358,952

^[1]

Transaction costs

240,399

1,191

Employee benefits

61,127

46,283

^[1]

114,308

^[1]

Revaluation loss derivative financial instruments

184,967

^[1]

(472,388)

^[1]

Gain on modification of financial instruments

(32,789)

^[1]

Income tax gain

(111,126)

^[1]

(10,815)

^[1]

Total

(6,141,920)

(8,091,182)

^[1]

(12,819,865)

^[1]

Changes in:

Inventories

(355,950)

^[1]

866,573

^[1]

Trade and other receivables

(277,318)

15,651

^[1]

(108,483)

^[1]

Prepayments

140,937

219,266

^[1]

896,784

^[1]

Trade and other payables

63,279

(3,672,432)

^[1]

1,322,718

^[1]

Accrued expenses

101,475

(926,779)

^[1]

749,885

^[1]

Net cash used in operating activities

(6,113,547)

(12,811,427)

^[1]

(9,092,388)

^[1]

Cash flows from investing activities

Purchase of property and equipment

(103,087)

^[1]

Purchase of intangibles

^[1]

(2,243,776)

^[1]

Cash received from / (paid for) other financial assets

(15,688)

11,174

^[1]

Investment in an associate

(545,353)

^[1]

Interest received

3,326

562

^[1]

1,015

^[1]

Disposal of subsidiaries

108

2,141,707

^[1]

Net cash from / used in investing activities

(115,341)

1,608,090

^[1]

(2,242,761)

^[1]

Cash flows from financing activities

Proceeds from offerings and warrant exercises

7,372,209

11,694,183

^[1]

4,149,338

^[1]

Transaction costs

(717,589)

(875,116)

^[1]

(37,169)

^[1]

Proceeds from loans

2,782,415

^[1]

6,323,170

^[1]

Repayment of loan

(1,486,436)

^[1]

Repayment of lease liabilities

(137,762)

(128,451)

^[1]

(119,635)

^[1]

Interest paid

(11,692)

(165,099)

^[1]

(20,422)

^[1]

Net cash from financing activities

6,505,166

11,821,496

^[1]

10,295,282

^[1]

Net increase / (decrease) in cash and cash equivalents

276,278

618,159

^[1]

(1,039,867)

^[1]

Cash and cash equivalents at beginning of the period

^[1]

733,701

^[3]

16,641

1,080,341

Net effect of currency translation on cash and cash equivalents

(11,355)

98,901

^[1]

(23,833)

^[1]

Cash and cash equivalents at end of the period

$ 998,624

$ 733,701

^[1],[3]

$ 16,641

^[1]

[1]	Amounts have been represented from those previously published to reflect the change in the Company’s presentation currency from Swiss francs to US dollars (see Note 2).
[2]	Amounts have been re-presented from those previously published to reflect the change in the Company’s presentation currency from Swiss francs to US dollars (see Note 2).
[3]	Amounts have been represented from those previously published to reflect the change in the Company’s presentation currency from Swiss francs to US dollars (see Note 2).

Consolidated Statement of Financial Position - USD ($)

Dec. 31, 2024

Dec. 31, 2023

^[1]

Jan. 01, 2023

^[1]

Non-current assets

Property and equipment

$ 100,000

$ 1

Right-of-use assets

349,905

95,198

481,923

Intangible assets

4,627,072

4,208,930

Other non-current financial assets

103,345

95,070

209,991

Investment in an associate

1,931,335

2,872,623

Total non-current assets

7,111,657

7,689,964

4,900,845

Current assets

Inventories

12,587

Trade receivables

7,053

Other receivables

351,331

88,916

817,195

Prepayments

190,524

337,293

766,691

Derivative financial instruments

293,630

292,051

Cash and cash equivalents

998,624

733,701

^[2]

16,641

Total current assets

1,540,479

1,453,540

1,912,218

Total assets

8,652,136

9,143,504

6,813,063

Equity

Share capital

9,324

2,956

267,773

Share premium

(1,522,747)

23,889,332

216,923,016

Other reserves

11,109,165

5,129,585

84,113

Accumulated deficit

(3,030,636)

(21,346,630)

(226,262,915)

Total shareholders’ equity/(deficit) attributable to owners of the Company

6,565,106

7,675,243

(8,988,013)

Non-current liabilities

Non-current lease liabilities

238,691

371,451

Employee benefit liability

684,075

411,917

363,427

Deferred income

1,007,675

Deferred tax liabilities

136,061

Total non-current liabilities

922,766

411,917

1,878,614

Current liabilities

Loan

6,345,041

Current lease liabilities

122,362

118,430

127,398

Trade and other payables

552,049

523,367

5,312,293

Accrued expenses

489,853

414,547

2,137,730

Total current liabilities

1,164,264

1,056,344

13,922,462

Total liabilities

2,087,030

1,468,261

15,801,076

Total equity and liabilities

$ 8,652,136

$ 9,143,504

$ 6,813,063

[1]	Amounts have been represented from those previously published to reflect the change in the Company’s presentation currency from Swiss francs to US dollars (see Note 2).
[2]	Amounts have been represented from those previously published to reflect the change in the Company’s presentation currency from Swiss francs to US dollars (see Note 2).